Mouse study links acetaminophen pain relief to CB1 lipid signaling
Acetaminophen alters endogenous lipid signaling and attenuates pathological pain through a mechanism requiring diacylglycerol lipase, monoacylglycerol lipase and cannabinoid CB1 receptors in mice.
AI Summary
This preclinical animal study asked whether acetaminophen (APAP) reduces pathological pain in mice through the endocannabinoid system and enzymes that regulate endogenous lipids. In mouse models of post-surgical and inflammatory pain, APAP reduced mechanical hypersensitivity. Inhibiting diacylglycerol lipase (DAGL) or monoacylglycerol lipase (MAGL) blocked this effect, as did cannabinoid receptor antagonists that act throughout the body. A peripherally restricted antagonist did not block APAP’s analgesia, pointing to involvement of cannabinoid signaling outside the periphery, although the abstract does not establish the precise site of action.
APAP also increased corticosterone levels by more than twofold, reduced prostaglandins by more than fivefold in the brain and paw skin, and reduced up to 39% of the signaling lipids measured in inflamed animals, depending on the tissue. The findings suggest that APAP affects a broader network of endogenous lipid signals than previously recognized. Because this was a mouse study, the abstract-based results cannot establish that the same mechanism operates in humans, that APAP’s effects are clinically important in people, or that cannabis or cannabinoid products would produce the same outcome.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Pain research papers you might find interesting.
Interviews explore how adults with regular pain perceive cannabis use
An 18-month cohort found adverse outcomes were infrequent, but long-term risks…
Language models can extract documented cannabis use, but need validation
Explore More Research
Stay informed about the latest cannabis science.